Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study

被引：7

作者：

Antonia, Scott Joseph

Brahmer, Julie R.

Balmanoukian, Ani Sarkis

Kim, Dong-Wan

Kim, Sang-We

Ahn, Myung-Ju

Jamal, Rahima

Jaeger, Dirk

Ott, Patrick Alexander

Ascierto, Paolo Antonio

Gregorc, Vanesa

Goldman, Jonathan Wade

Blakely, Collin M.

Jin, Xiaoping

Antal, Joyce

Gupta, Ashok Kumar

Segal, Neil Howard

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[3] Angeles Clin & Res Inst, Los Angeles, CA USA

[4] Seoul Natl Univ Hosp, Seoul, South Korea

[5] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[6] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[7] Univ Montreal, CHUM Res Ctr CRCHUM, Hopital Notre Dame, CHUM, Montreal, PQ, Canada

[8] Univ Heidelberg Hosp, Natl Ctr Tumor Dis NCT, Heidelberg, Germany

[9] Dana Farber Canc Inst, Boston, MA USA

[10] Ist Nazl Tumori Fondazione G Pascale IRCCS, Naples, Italy

[11] IRCCS Osped San Raffaele, Dept Med Oncol, Milan, Italy

[12] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA

[13] Univ Calif San Francisco, Dept Med, San Francisco, CA USA

[14] MedImmune, Gaithersburg, MD USA

[15] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

来源：

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.e20504

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e20504

引用

页数：6